A Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors.

Trial Profile

A Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Everolimus (Primary) ; Lapatinib (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 04 Oct 2012 Planned end date changed from 1 Aug 2007 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top